Decision Diagnostics (Decision Diagnostics) Net Change in Cash : $-0.13 Mil (TTM As of Sep. 2021)

View and export this data going back to . Start your Free Trial

What is Decision Diagnostics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Decision Diagnostics's Net Change in Cash for the three months ended in Sep. 2021 was $-0.06 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.13 Mil.

Decision Diagnostics Net Change in Cash Historical Data

The historical data trend for Decision Diagnostics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Decision Diagnostics Net Change in Cash Chart

Decision Diagnostics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec17

Dec18

Dec19

Dec20

Net Change in Cash

Get a 7-Day Free Trial

0.07

-0.26

-0.73

-0.54

0.71

Decision Diagnostics Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Net Change in Cash	Get a 7-Day Free Trial															-0.07	0.24	-0.08	-0.22	-0.06

Decision Diagnostics Net Change in Cash Calculation

Decision Diagnostics's Net Change in Cash for the fiscal year that ended in Dec. 2020 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-1.405	+	0.05	+	2.063	+	0
	=	0.71

Decision Diagnostics's Net Change in Cash for the quarter that ended in Sep. 2021

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.06 + -0.002 + 0 + 0

= -0.06

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decision Diagnostics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Decision Diagnostics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Decision Diagnostics (Decision Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Decision Diagnostics Corp (OTCPK:DECN) » Definitions » Net Change in Cash

Comparable Companies

JSE:AMS JSE:NPH JSE:THA JSE:GML JSE:RBP WBA BSP:RADL3 SAU:4164 HKSE:00241 TSE:3088 SHSE:603939 TSE:3141 TSE:3349 JSE:CLS SHSE:600998 TSE:9989 TSE:3391 TSE:7649 SHSE:603883 SZSE:002727

Traded in Other Exchanges

N/A

Address

2660 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361

Website

http://www.decisiondiagnostics.co

Decision Diagnostics Corp is a provider of prescription drugs, home testing products for the chronically ill, direct to patient diabetes programs, and a developer of revolutionary, cell phone centric, e-health products and technology. The company also provides blood glucose home testing test strips and exciting new concepts for blood testing monitors.

Executives

Keith Berman director, officer: Secretary 2660 TOWNSGATE RD #300, WESTLAKE VILLAGE CA 91361

Robert Jagunich director 765 CHRISTINE DR PALO ALTO CA 94303

Robert Lawrence Cox director, officer: President

Decision Diagnostics (Decision Diagnostics) Headlines

From GuruFocus

DECN to Announce Various Testing Results This Week for Its COVID-19 GenViro! Swift Kit
By ACCESSWIRE ACCESSWIRE • 12-21-2020

DECISION DIAGNOSTICS CORP. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a federal securities class action lawsuit against Decision Diagnostics Corp.
By Marketwired Marketwired • 01-20-2021

DECN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Decision Diagnostics Corp. Investors of Class Action and Encourages Shareholders to Contact the Firm
By PRNewswire PRNewswire • 01-19-2021

DECISION DIAGNOSTICS DEADLINE ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options
By Marketwired Marketwired • 01-23-2021

ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors With Losses in Excess of $500K to Secure Counsel Before Important March 16 Deadline � DECN
By Marketwired Marketwired • 03-03-2021

DECN Secures Exclusive Distributor Agreement With a German Based Company for the Distribution of Genviro! Covid-19 :10 Saliva Testing Kits and Meters in 18 EU Countries, Norway and the UK
By ACCESSWIRE ACCESSWIRE • 12-10-2020

DECN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Decision Diagnostics Corp. Investors of Class Action and Encourages Shareholders to Contact the Firm
By Marketwired Marketwired • 01-21-2021

DECISION DIAGNOSTICS DEADLINE ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options
By Marketwired Marketwired • 01-19-2021

DECISION DIAGNOSTICS CORP. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against Decision Diagnostics Corp.
By Marketwired Marketwired • 02-23-2021

DECN, PEN & WMT Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
By Marketwired Marketwired • 02-16-2021

Keith Berman	director, officer: Secretary	2660 TOWNSGATE RD #300, WESTLAKE VILLAGE CA 91361
Robert Jagunich	director	765 CHRISTINE DR PALO ALTO CA 94303
Robert Lawrence Cox	director, officer: President